07:00 , Apr 15, 2013 |  BioCentury  |  Finance

De-risking money

De-risking money Cleave Bioscience Inc.'s investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is tied to...
07:00 , Mar 25, 2013 |  BioCentury  |  Emerging Company Profile

Cleave: Proteasome alternatives

Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors. The...
08:00 , Mar 1, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens RNA sequencing of multiple drug-resistant cells to identify therapeutic targets and mechanisms of action In vitro studies suggest...
07:00 , Oct 12, 2009 |  BioCentury  |  Emerging Company Profile

BerGenBio: Controlling Interference

Conventional RNAi methods can neither control nor vary the extent to which a protein's expression is blocked, and so provide only rough insights into target function at one level of inhibition. BerGenBio A/S says its...